Boston Partners Has $11.94 Million Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Boston Partners cut its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 0.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 423,070 shares of the company’s stock after selling 3,566 shares during the period. Boston Partners owned about 0.89% of Amphastar Pharmaceuticals worth $11,943,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. TD Asset Management Inc raised its holdings in Amphastar Pharmaceuticals by 20.2% in the first quarter. TD Asset Management Inc now owns 2,212,142 shares of the company’s stock worth $64,130,000 after purchasing an additional 371,856 shares during the period. Boston Trust Walden Corp raised its holdings in Amphastar Pharmaceuticals by 24.2% in the first quarter. Boston Trust Walden Corp now owns 1,215,624 shares of the company’s stock worth $35,241,000 after purchasing an additional 236,704 shares during the period. Dimensional Fund Advisors LP raised its holdings in Amphastar Pharmaceuticals by 9.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company’s stock worth $44,503,000 after purchasing an additional 105,288 shares during the period. Northern Trust Corp raised its holdings in Amphastar Pharmaceuticals by 5.1% in the fourth quarter. Northern Trust Corp now owns 613,170 shares of the company’s stock worth $22,767,000 after purchasing an additional 29,808 shares during the period. Finally, Marshall Wace LLP raised its holdings in Amphastar Pharmaceuticals by 7.1% in the fourth quarter. Marshall Wace LLP now owns 608,706 shares of the company’s stock worth $22,601,000 after purchasing an additional 40,212 shares during the period. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on AMPH shares. Needham & Company LLC upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a report on Tuesday. JPMorgan Chase & Co. restated a “neutral” rating and set a $30.00 price objective (down from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Piper Sandler dropped their price objective on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a report on Friday, August 8th. Finally, Wells Fargo & Company dropped their price objective on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday, May 8th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $31.50.

Amphastar Pharmaceuticals Stock Down 1.3%

Amphastar Pharmaceuticals stock opened at $29.83 on Friday. The company has a market cap of $1.39 billion, a P/E ratio of 11.17 and a beta of 0.76. Amphastar Pharmaceuticals, Inc. has a 1-year low of $20.39 and a 1-year high of $53.96. The company has a fifty day simple moving average of $23.74 and a 200 day simple moving average of $26.03. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.